Biblio
Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024:JCO2301277.
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun. 2023;14(1):5335.
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022;8:e2200119.
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Am J Hematol. 2020.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. Biol Blood Marrow Transplant. 2020.
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom. 2015.
. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2015.